Fulcrum Therapeutics (FULC) Cash from Financing Activities (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Cash from Financing Activities of $356000.0 for Q2 2026, up 18.27% year-over-year from $301000.0 in Q2 2025, and up 214.1% quarter-over-quarter from -$312000.0 in Q1 2026.
Fulcrum Therapeutics (FULC) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Cash from Financing Activities for 9 consecutive years, with $356000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 18.27% year-over-year to $356000.0; the TTM figure through Jun 2026 stood at $168.4 million (up 16426.99% YoY), while the FY2025 annual figure was $168.7 million, up 6042.28% from the prior year.
- Cash from Financing Activities grew to $356000.0 in Q2 2026 per FULC's latest filing, from -$312000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $168.3 million in Q4 2025 and bottomed at -$312000.0 in Q1 2026.
- Historically, Cash from Financing Activities has averaged $23.4 million across 5 years, with a median of $352000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 99.27% — and 2025, when it soared 202673.49%.
- Fulcrum Therapeutics' Cash from Financing Activities stood at $218000.0 in 2022, then surged by 31.65% to $287000.0 in 2023, then slumped by 71.08% to $83000.0 in 2024, then jumped by 202673.49% to $168.3 million in 2025, then tumbled by 99.79% to $356000.0 in 2026.
- Business Quant data shows FULC's Cash from Financing Activities at $356000.0 in Q2 2026, -$312000.0 in Q1 2026, and $168.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 356,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 356,000.00 |
| Jun 30, 2026 | 356,000.00 |
| Mar 31, 2026 | -312,000.00 |
| Mar 31, 2026 | -312,000.00 |
| Dec 31, 2025 | 168.30 Mn |
| Dec 31, 2025 | 168.30 Mn |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 635,000.00 |
| Sep 30, 2024 | 635,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Mar 31, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 287,000.00 |
| Dec 31, 2023 | 287,000.00 |